Phase III Clinical Results of Rotavirus Vaccine Trials and Efforts to Accelerate Introduction to the Developing World

John W. Boslego MD PATH 27 July 2006



Outline

- I. Background
- II. RotaTeq[®] (Merck)
- III. Rotarix[®] (GSK)
- IV. Accelerated Development and Introduction Plan (ADIP)
- V. Summary



Outline

- I. Background
- II. RotaTeq[®] (Merck)
- III. Rotarix[®] (GSK)
- IV. Accelerated Development and Introduction Plan (ADIP)
- V. Summary



2006 An incredible year for Rotavirus Vaccines

- 1. US FDA licenses RotaTeq[®].
- 2. ACIP recommends RotaTeq[®] for routine immunization of all American children.
- 3. EMEA licenses Rotarix[®].
- 4. Brazil and Panama begin national programs of childhood immunization.
- 5. >30 countries have licensed a RV vaccine.



The Saga of Rotashield®

- Live, human-rhesus rotavirus reassortant vaccine
- Licensed in 1998, but withdrawn from market in 1999 due to unexpected, increased risk of intussusception
- Abrupt demise of first vaccine licensed after 20 years of research
- Vaccine licensed by NIH to BioVirix, Inc, in 2004
- Seeking commercialization, but no success to date



Challenges of Rotavirus Vaccine Development in Face of Intussusception

- Design a study that is large enough to provide a meaningful evaluation of an uncommon event, yet feasible to implement prelicensure.
- Develop a safety monitoring system to detect a potential increased risk of intussusception early and minimize risk to trial participants.
- Decide on safety criteria for demonstrating that the vaccine is clinically acceptable for licensure.



RotaTeq[®] and Rotarix[®]

Characteristic	RotaTeq®	Rotarix®
Manufacturer	Merck	GSK
Parent strain	Bovine Rotavirus strain WC3	Human Rotavirus strain 89-12
Method of Attenuation	Animal strain naturally attenuated; further passaged 7-69 times	Passaged 43 times
Final Vaccine	Live, human-bovine rotavirus reassortants (G1, G2, G3, G4, P1A[8])	Live, attenuated human rotavirus (G1, P1A[8])
Presentation	Oral suspension in liquid buffer (2 mL)	Lyophilized, reconstituted with liquid diluent prior to administration (1 mL)
Buffer	Citrate phosphate sucrose	Calcium carbonate



RotaTeq[®] and Rotarix[®] continued

Characteristic	RotaTeq®	Rotarix®
Route of administration	Oral, administered directly from tube; no restriction on food or liquid	Oral, administered by syringe, no restriction on food or liquid
Dose (end of shelf-life)	~ 2-3 x 10 ⁶ /virus; ~ total 1-1.5 x 10 ⁷ infectious units	~ 1 x 10 ⁶ infectious units
Cell substrate	Vero cells	Vero cells
Storage	2°-8° C	2°-8° C
Shelf life	24 months	36 months
Regimen	3 doses, 1 st at 6-12 wks, subsequent dose at 4-10 wk intervals	2 doses, 1 st at 6-14 wks, 2 nd at 1-2 mo interval
Post-dose shedding	~10%	>50%




Outline

- I. Background
- II. RotaTeq[®] (Merck)
- III. Rotarix[®] (GSK)
- IV. Accelerated Development and Introduction Plan (ADIP)
- V. Summary



Bovine (WC3) Rotavirus



10 Human-Bovine Reassortment Rotavirus Vaccine Strains

Rotavirus Efficacy and Safety Trial (REST) Study Design

- Sample size: ≥ 60,000 (randomized 1V:1P) Additional groups of 10,000 subjects enrolled until primary safety criteria met or 100,000 subjects enrolled
- Age: 6 to 12 weeks at first dose
- Regimen: 3 oral doses, 1 every 4 to 10 weeks
- Sites: Areas with good standard of care for intussusception
- Duration: January 2001 to April 2005




71,799 Subjects in 11 Countries Vaccinated 36,203 in RotaTeq[®] Group 35,596 in Placebo Group






REST Intussusception Results



No intussusception cases in Protocols 007 and 009

Confirmed Intussusception Cases in REST Within 1 Year of Dose 1

13 Vaccine : 15 Placebo RR=0.9; 95% CI=0.4, 1.9



Primary Efficacy Hypotheses Were Met - RotaTeq[®] Was Efficacious Against G1-4 Rotavirus Gastroenteritis

Efficacy Cohort

	Vaccine (N=3484)		% Efficacy	95% CI
Any	97	369	73.8	67.2,79.3
Severe	1	57	98.2	89.6,100.0

N=number vaccinated.



RotaTeq[®] Was Efficacious Against Hospitalizations, Emergency Department Visits & Office Visits for G1-4 Rotavirus Gastroenteritis

REST

Type of Health	Number	<u>of Cases</u>	% Rate	
Type of Health <u>Care Encounter</u>	<u>Vaccine</u>	<u>Placebo</u>	Reduction	<u>95% CI</u>
Hospitalizations [†]	6	144	95.8	90.5, 98.2
Emerg. Dept. Visits [†]	14	225	93.7	88.8, 96.5
Office Visits [‡]	13	98	86.0	73.9, 92.5

[†] N=34,035 vaccinated in vaccine group and 34,003 vaccinated in placebo group.
[‡] N=2834 vaccinated in vaccine group and 2839 vaccinated in placebo group.



Outline

- I. Background
- II. RotaTeq[®] (Merck)
- III. Rotarix[®] (GSK)
- IV. Accelerated Development and Introduction Plan (ADIP)
- V. Summary



Rotarix®

- G1, P1A[8] human virus attenuated by passage through cell culture
 - Shares neutralizing epitopes with G1, G3, G4, and G9 RV types


Rotarix[®] Pivotal Phase 3 Trial: Latin America and Finland

Primary immunization phase: Analysis of intussusception and safety (N>63,000 infants)

1-year follow-up: Nested analysis of efficacy and safety (N>20,000 infants)




Rotarix[®] intussusception (IS) data



Ruiz-Palacios G. et al N. Engl. J. Med. 2006; 354: 11-22

20

Intussusception: Rotarix[®] Compared With RotaShield[®]



Ruiz-Palacios et al: NEJM 2006,354 11-22

Efficacy of Rotarix[®] against RVGE

Number of Cases

Disease <u>Severity</u>	HRV <u>(N=9009)</u>	Placebo (N=8858)	% Efficacy	<u>95% CI</u>
Severe	12	77	84.7	71.7, 92.4
Hospitalized	9	59	85.0	69.6, 93.5

Ruiz-Palacios G. et al N. Engl. J. Med. 2006; 354: 11-22



Efficacy of Rotarix[®]: Serotype Specific Against Rotavirus Disease of Any Severity

-	Cases, N		-	
Serotype	Vaccine (n=9009)	Placebo (n=8858)	% Efficacy	95% CI
G1	3	36	91.8	74.1, 98.4
G2	1	6	41.0	<0.0, 82.4
G3, G4 or G9	4	31	87.3	64.1, 96.7

Outline

- I. Background
- II. RotaTeq[®] (Merck)
- III. Rotarix[®] (GSK)
- IV. Accelerated Development and Introduction Plan (ADIP)
- V. Summary



PATH's Rotavirus Vaccine Program (RVP) Goals

- **Goal 1:** Provide information that enables national decision-makers, and the GAVI Board and its partners, to make evidence-based decisions regarding the use of rotavirus vaccines.
- **Goal 2:** Accelerate the availability of new rotavirus vaccines appropriate for use in developing countries.



Building the Evidence Base

Disease burden (global/country)

Disease surveillance

- Serotype distribution
- Intussusception surveillance

 Clinical trials in developing countries (Asia,

Vaccine safety and efficacy

(regional)

Africa)

 Economic burden of preventable illness/death

Economics

(global/country)


 Cost-effectiveness of vaccination

²⁶ Rotavirus ADIP agenda



Vaccine Introduction Scenario Perspective

Million doses



Source: McKinsey & Co.; PATH's Rotavirus Vaccine Program

27

Will live oral rotavirus vaccines work well for children in Africa and Asia?

- Live oral vaccines less efficacious in developing world
- Differences in nutritional status, breastfeeding patterns, bacterial and parasitic infections, HIV prevalence



Different rotavirus serotypes




Will live oral rotavirus vaccines work well for children in Africa and Asia – how many efficacy trials are needed?

	GSK: Human, monovalent	Merck: Bovine reassortment, multivalent
Africa	Phase III Underway	Phase III target start date: late 2006
Asia	GSK Phase II: Bangladesh, India, Vietnam	Phase III target start date: early 2007




How Many Doses are Required for GAVI-eligible Countries?



30

How Many Lives Can Be Saved with Accelerated Rotavirus Vaccine Introduction?



1 Adapted from Rheingans et.al 2005 (unpublished) and Parashar 2003; Range: 0.9 to 2.3 Million Lives Saved 2Adapted from Rheingans et.al. 2005 (unpublished) and Parashar 2003: 130 hospitalizations and outpatient visits avoided per 1000 infants vaccinated 3 Based on avg. cost per visit = \$5.00

31

Outline

- I. Background
- II. RotaTeq[®] (Merck)
- III. Rotarix[®] (GSK)
- IV. Accelerated Development and Introduction Plan (ADIP)
- V. Summary



Summary

- Rotavirus prevention efforts were set back by the withdrawal of *RotaShield*[®]
- New safe and effective rotavirus vaccines offer the best hope of reducing the toll of acute rotavirus gastroenteritis in developed and developing countries
- *RotaTeq[®]* and *Rotarix[®]* have demonstrated safety and efficacy in controlled clinical trials and licensure efforts are underway around the globe.
- Accelerated implementation programs are striving to deliver these vaccines to areas where they are needed most.



John Boslego, MD Director, Vaccine Development jboslego@path.org 202.822.0033

www.path.org



Backup Slides




Rhesus Rotavirus Vaccine --Rotashield[®]

- Live oral vaccine
- 3 doses given at 2, 4, 6 months
- Safety mild fevers on day 3-5 <10%
- Efficacy 70% against mild RV diarrhea, >85% against severe RV diarrhea




Characteristics of Naturally-Occurring Intussusception



•Etiology not well defined •Uncommon: Incidence ~1/2000 infant-years •Peak incidence is between 5 and 9 months of age •Male to female case ratio = 1.5-4:1•Treated with enema or surgery •Morbidity and mortality low if treated early; however, delay in

Interval between Rotashield vaccine and Intussusception



Murphy TV, et al, 2001

PATH

PATH creates sustainable, culturally relevant solutions that enable communities worldwide to break longstanding cycles of poor health by:

- Advancing technologies, e.g. vaccines malaria, meningococcal, rotavirus, HPV, JE, pneumococcal
- Strengthening health systems
- Encouraging healthy behaviors

Visit www.path.org

